Sector consensus Neurogene Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 10/02/2026 GMT			5-day change	1st Jan Change
17.00 ^USD	-3.52%		-3.19%	-17.48%

02-04	Neurogene announces inducement grant under Nasdaq Listing Rule	RE
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Average Target P.	Objective/dr gap	Nbr of analysts
NEUROGENE INC.	US$57.2	+236.47%	5
LONZA GROUP AG	CHF 674.7	+30.6%	23
BEONE MEDICINES AG	US$406	+14.88%	24
CELLTRION, INC.	₩250,652.17	+10.18%	23
IQVIA HOLDINGS INC.	US$246.1	+34.89%	20
REVOLUTION MEDICINES, INC.	US$119.37	+24.37%	19
MEDPACE HOLDINGS, INC.	US$507.67	+13.81%	12
EUROFINS SCIENTIFIC SE	€70.26	+4.18%	15
IONIS PHARMACEUTICALS, INC.	US$91.13	+8.11%	22
ASCENDIS PHARMA A/S	US$233.91	+23.02%	16
ICON PUBLIC LIMITED COMPANY	US$206.38	+42.77%	16
QIAGEN N.V.	US$54.61	+6.9%	14
BIO-TECHNE CORPORATION	US$75.25	+16.13%	12
TEMPUS AI, INC.	US$87.92	+57.33%	12
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	US$215.73	+19.03%	15
ABIVAX	€108.46	+7.39%	5
PRAXIS PRECISION MEDICINES, INC.	US$572.88	+78.76%	16
HANGZHOU TIGERMED CONSULTING CO., LTD	CN¥68.9	+3.46%	11
Average	14,136.03	+35.13%	16
Weighted average by Cap.	28,719.01	+22.83%	19